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Abstract
Water-soluble polyphosphazene polyacids, such as poly[di(carboxylatophenoxy)
phosphazene] (PCPP), have been of significant interest due to their unique
immunoadjuvant and vaccine delivery properties. We report that PCPP can
spontaneously self-assemble into intermolecular complexes with common
formulation excipients − polyethers in aqueous solutions at neutral pH through the
establishment of hydrogen bonds. The resulting advanced PCPP delivery
modalities can range from macromolecular assemblies at the nanoscale level to
physically cross-linked hydrogels and the physical state can be modulated through
varying polymer ratios and molecular weight of polyether. It has been
demonstrated that such macromolecular complexes maintain protein-binding
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modification of PCPP immunoadjuvant with polyethers introduces pH dependent
membrane disruptive activity, which is not characteristic for PCPP itself, and is
typically correlated to the ability of macromolecular carrier to facilitate endosomal
escape. This can potentially affect the mechanism of immunoadjuvant action
displayed by PCPP, afford means for its fine-tuning, as well as provide important
insights for understanding the relationship between fundamental physico-chemical
characteristics of polyphosphazene immunoadjuvants and their activity in vivo.
Keywords: Biochemistry, Immunology, Pharmaceutical science, Biotechnology,
Bioengineering, Physical chemistry
1. Introduction
Polyphosphazene polyacids, a class of polyelectrolytes with an inorganic
backbone, have gained significant attention primarily due to their unique
immunoadjuvant activity in vivo. When administered with vaccine antigens, these
ionic macromolecules display a dramatic immunopotentiating effect manifested in
improved magnitude, quality, onset, and duration of immune responses, as well as
in a substantial vaccine sparing capability [1, 2, 3, 4]. The lead polyphosphazene
adjuvant − poly[di(carboxylatophenoxy)phosphazene], PCPP has been advanced
into clinical trials and PCPP adjuvanted vaccines were reported to be safe and
immunogenic in humans [5, 6]. From a physico-chemical perspective, the ability
of this polymer to spontaneously bind antigenic proteins, as well as to interact with
immunocompetent cells, which in turn leads to cell maturation and more effective
antigen processing, plays a fundamental role in biological activity of PCPP [7, 8].
Further studies of this polymer explored its protein stabilization effect [9],
hydrolytic degradation [10], microencapsulation [11], and microfabrication for
transdermal delivery of vaccines [12]. However, there is only limited knowledge
on the solution behavior of PCPP, its interactions with formulation components
and excipients, and the effect of such interactions on biological activity of
polyphosphazene.
It has been already observed that functional properties of PCPP can be
significantly altered upon introduction of certain formulation excipients. For
example, an addition of non-ionic surfactants or poly(ethylene oxide) (PEO)
causes a dramatic enhancement of protein-stabilizing properties and modifies
degradation profiles of polyphosphazenes in an aqueous environment at neutral
pH [9, 10]. Although the importance of such additives and their effect on
functional activity of polyphosphazene is clear, the mechanism of these
phenomena is poorly understood. In this regard, the formation of interpolymer
hydrogen bonds in such formulations can provide a reasonable explanation for
prior findings. However, it is well established that the formation of interpolymer
complexes depends on the degree of ionization of poly(carboxylic acid) and thus
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on environmental pH. Typically, such complexes are only formed in weakly or
strongly acidic media and dissociate upon increase in pH, which limits their
in vitro and in vivo utility [13, 14, 15].
In light of the above, it was important to explore if PCPP has a potential to
self-assemble at neutral pH through the formation of hydrogen bonds. Moreover,
it remained unclear if the formation of such complexes can result in the
modulation of fundamental properties related to its immunomodulating activity.
The present paper investigates interactions between immunopotentiating
polyphosphazene polyelectrolyte, PCPP, and polyethers in aqueous solutions.
Here, we report on the spontaneous self-assembly of polyphosphazene
macromolecule and PEO at neutral pH into interpolymer complexes and we
investigate some of their critical biological properties, such as protein binding
affinity and pH dependent membrane activity in interactions with cells.
2. Materials and methods
2.1. Materials
Poly[di(carboxyatophenoxy)phosphazene], sodium salt (PCPP), molecular weight
800,000 g/mol, was synthesized as described previously [16]. Polyoxyethylene
(PEO), poly(ethylene oxide) or poly(ethylene glycol), with molecular weights of
8,000, 300,000, 665,000 (Alfa Aesar, Ward Hill, MA), 35,000 (EMD Chemical
Inc. Gibbstown, NJ), 100,000 g/mol (Sigma-Aldrich, St. Louis, MO), Albumin
from Bovine Serum, FITC conjugate, FITC-BSA (Sigma-Aldrich, St. Louis,
MO), sodium phosphate dibasic heptahydrate; sodium phosphate monobasic;
potassium phosphate monobasic (Sigma, St Louis, MO); and Dulbecco’s
Phosphate Buffered Saline, PBS (Sterile, without Calcium or Magnesium,
Lonza, Walkersville, MD), 10% suspension of Porcine Red Blood Cells (RBC)
in PBS (Innovative Technology Inc., Novi, MI) were used as received.
2.2. Preparation of PCPP-PEO and PCPP-PEO-protein
formulations
Formulations were prepared by mixing aqueous solutions of PCPP and PEO in
the appropriate media, typically 50 mM phosphate buffer or PBS, and vortexing
them for 0.5 min. For protein containing formulations, solutions of Cytochrome
C in aqueous PBS (pH 7.4) were added. Formulation components were filtered
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2.3. Evaluation of membrane disruptive activity
The membrane disruptive activity of multifunctional carriers, which can be
correlated to the ability of the carrier to facilitate endosomal escape and
cytosolic delivery of pharmaceutical agent, was tested as described previously
[17, 18, 19]. 100 μL of fresh Porcine Red Blood Cells (RBC) as a 10%
suspension in phosphate buffered saline (PBS) (Innovative Technology Inc.,
Novi, MI) was re-suspended in 900 μL of PBS. 50 μL of re-suspended RBC
was added to 950 μL of the PCPP-PEG or PCPP formulation in PBS at the
appropriate pH, inverted several times for mixing, and incubated in a 37 °C for
60 min. Cells were then centrifuged at 14,000 rpm for 5 min, and the
absorbance of the supernatant was then measured at 541 nm using Multiskan
Spectrum microplate spectrophotometer (ThermoFisher Scientific, Waltham,
MA). To determine 100% hemolysis, RBCs were suspended in distilled water
and lysed by ultrasound (Branson Sonifier, Model 450). All hemolysis
experiments were done in triplicate.
2.4. Dynamic light scattering (DLS) analysis
Hydrodynamic radii and Zeta potentials of polymers in aqueous solutions was
carried out using ZetaSizer Nano series, ZEN3500, (Malvern Instruments Ltd.,
Worcestershire, UK). Formulation components were filtered using 0.22 μm
Millex syringe filters (EMD Millipore, Billerica, MA) before mixing.
2.5. Analysis of protein content using high performance liquid
chromatography
Size exclusion − high performance liquid chromatography (SEC-HPLC) of the
formulation was performed using a Hitachi HPLC system with an L-2450 diode
array detector (Hitachi LaChrom Elite system, Hitachi, San Jose, CA) equipped
with an Ultrahydrogel Linear size exclusion column (Waters Corporation,
Milford, MA) at 25 °C using 1x PBS as a mobile phase with a flow rate of
0.75 mL/min. Peak area and retention time of the peak attributed to Cytochrome
C was monitored at 280 nm. The content of bound protein was determined by
subtracting the amount of Cytochrome C detected by HPLC and the total
amount of protein used in the formulation. The loading of protein was
calculated as a weight ratio between bound Cytochrome C and a complex and
the efficiency of protein binding was defined as a weight ratio between bound
and total amount of protein added to the system.
2.6. Turbidimetric titration
Turbidimetric titration was performed at an ambient temperature by measuring
the absorbance/transmittance (T) of the mixture at 420 nm (UV/Vis
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Spectrophotometer, HITACHI U-2810, Hitachi, San Jose, CA) using 2 ml
cuvettes with 1 cm path length. Polymer solutions were filtered using 0.2 μm
Millex filters (EMD Millipore, Billerica, MA) prior to titration. Solutions were
vortexed for 15 seconds after addition of the titrant and monitored in the
spectrophotometer until a stable turbidity reading (±0.1% T) was obtained.
2.7. Potentiometric titration
Potentiometric titration was conducted using Mettler-Toledo FiveEasy® FE20
pH Meter equipped with InLab® MicroPro pH electrode (Mettler-Toledo,
Columbus, OH). Aliquots of PEO solutions were added to 0.5 mg/mL solutions
of PCPP in deionized water in the presence or absence of 0.9% sodium chloride.
After each addition of the titrant, the pH was allowed to equilibrate until stable
reading was obtained, typically for approximately 2 minutes. The initial pH of
PCPP solutions of PCPP was adjusted to pH 7.40–7.45 by adding 0.01 N
solution of hydrochloric acid.
2.8. Fluorescent microscopy
Fluorescent microscopy examination was conducted using ECLIPSE 80I
fluorescent microscope (Nikon Instruments, Melville, NY).
3. Results and discussion
3.1. PCPP-PEO complex formation at neutral pH: phase
separation, coacervation, and macromolecular self-assembly in
solutions
The ability of PCPP (Fig. 1A) to form interpolymer complexes with PEO at
neutral pH through the establishment of hydrogen bonds (Fig. 1B) has been
investigated using DLS, fluorescent microscopy, turbidimetric, and
potentiometric titration methods. Method selection was dictated primarily by the
[(Fig._1)TD$FIG]
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solubility and physical state of the complex, which varied depending on the
reaction conditions, ratio of reagents, and their molecular weights. Such
diversity can potentially offer ample opportunities for fine-tuning formulations
for various drug delivery applications.
The formation of insoluble complexes in the system was studied using
turbidimetric titration of PCPP solutions with PEO in phosphate buffer at pH
7.4. The addition of polyether with the molecular weight of 300,000 g/mol to
PCPP solution led to distinct phase separation at various concentrations of PEO
(Fig. 2A). The section of the curves corresponding to low ether to acid
equivalent ratio (below unity in Fig. 2B) was characterized with a very low
optical density, which suggests the presence of colloidal solution. It was found
that the formation of insoluble complexes is only limited to polyethers of high
molecular weight (Fig. 2C) with no phase separation detected for PEO with the
molecular weight below 35,000 g/mol.
Soluble PCPP-PEO formulations were also titrated with aqueous sodium
chloride, which, as was shown previously [16], can cause precipitation of PCPP.
Phase separation was observed in all formulations, however distinct shifts in
turbidimetric titration profiles were detected, which were proportional to the
amount of PEO added to the system (Fig. 2D). Since precipitation of PCPP with
sodium chloride can be explained by electrostatic screening of the repulsion
interactions along the polymer chain [16], the differences in titration curves can
be the result of varying charge density of PCPP as a function of PEO
concentration. A reduction in the number of ionized carboxyl groups of PCPP in
the presence of PEO may indicate the occurrence of interactions in soluble
PCPP-PEO systems as well.
Further studies of soluble and colloidal systems were carried out using
potentiometric titration in deionized water. Prior to titration, the pH of PCPP
solution was adjusted to pH 7.4. The analysis was performed on the basis of
well-established fact that hydrogen bond formation shifts polyacid dissociation
equilibrium towards the non-dissociated form resulting in an increase of the
solution pH [20, 21].
The potentiometric profiles demonstrate a pronounced increase in pH, which
was dependent on the concentration of PCPP (Fig. 3A). This effect was
observed for polyethers with molecular weights ranging between 30,000 and
300,000 (Fig. 3B), which demonstrates formation of water-soluble complexes
even with low molecular weight polyethers. The change in pH for the
investigated systems was leveled off upon achieving the ratio of ether to acid
groups at approximately 1:2, which can be considered as an endpoint of titration
[20, 21]. The degree of complex conversion (the fraction of bonded carboxylic
groups) for PCPP titration with polyethers of various molecular weights levels
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off at approximately 0.4 (Fig. 3C) indicating that almost half of functional
groups of PCPP can be involved in the complex formation.
Formulations in the intermediate PEO:PCPP range, which displayed some
turbidity in the absence of precipitation, were also studied using fluorescent
[(Fig._2)TD$FIG]
Fig. 2. Turbidimetric titration of (A, B) PCPP with PEO at various PCPP concentrations − 0.025%
(1), 0.05% (2) and 0.075% (3) (0.2% PEO of 300,000 g/mol); (C) PCPP with PEO of various
molecular weights − 665,000 (1), 300,000 (2), 100,000 (3), 35,000 (4), and 8,000 (5) g/mol (0.05%
PCPP, 0.25% PEO, 420 nm, 0.05 M phosphate buffer, pH 7.4), and (D) PCPP with sodium chloride
in the presence of 0% (1), 0.002% (2), 0.005% (3) 0.01% (4), 0.02% (5) of PEO (0.05% PCPP,
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microscopy. To visualize the particulates, a fluorescently labeled protein,
FITC-BSA, was added to PCPP-PEO formulations. The particulates in
micrometer size range were observed (Fig. 4), although with a somewhat broad
size distribution. The primarily spherical shape of stained microparticulates,
which can be seen in the Figure, suggests coacervation of hydrogen bond
complexes under these conditions and some internalization of fluorescently
[(Fig._3)TD$FIG]
Fig. 3. Potentiometric titration of PCPP with PEO at (A) various concentrations of PCPP − 0.05%
(1) and 0.2% (2) (molecular weight of PEO − 300,000 g/mol), and (B) various molecular weights of
PEO − 8,000 (1), 100,000 (2), 300,000 (3) (1% PEO, deionized water, 25 °C). (C) Degree of
complexation (θ) as a function of the ratio of functional groups in PEO and PCPP for various
molecular weights − 8,000 (1), 100,000 (2), 300,000 g/mol (3) of PEO (0.05% PCPP, deionized
water, 25 °C).
[(Fig._4)TD$FIG]
Fig. 4. Physical states of PCPP-PEO system at various ratios between carboxyl and ether groups
(pH 7.4, 0.05% of PCPP, molecular weight of PEO − 300,000 g/mol, 0.05 M phosphate buffer).
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labeled protein in a polymer rich phase. These findings may indicate a potential
of PCPP-PEO system for protein encapsulation and drug delivery applications.
The above characterization results suggest the occurrence of three distinct
physical states for PCPP-PEO systems in aqueous media at neutral pH
depending on the concentrations and molecular weights of the polymers (Fig. 4).
Clear or colloidal macromolecular solutions with self-assemblies in the
100–1000 nm size range are typical for low molecular weight polyethers or at a
low PEO:PCPP ratio. Microparticles or coacervate systems can be obtained at
intermediate ether-acid ratios for high molecular weight polyethers. Finally, the
precipitate can be also formed in the systems with a large excess of high
molecular weight PEO. Interestingly, a slightly transparent appearance of the
precipitate suggests its high water content. The apparent hydrogel characteristics
of the insoluble complex suggest physical cross-linking in the system, which can
be further explored for biomaterials applications. These three physical states and
their boundaries are schematically exemplified for the PEO with the molecular
weight of 300,000 g/mol (Fig. 4) and designated on the basis of commonly
accepted classification of particulate systems [22]. Although coacervates and
hydrogels also present significant interest as delivery systems and biomaterials,
our present studies were further focused on soluble and colloidal formulations
due to well-established immunoadjuvant properties of water-soluble PCPP.
3.2. DLS studies of PCPP-PEO complex formation at near
physiological conditions
Formation of soluble PCPP-PEO complexes in aqueous solutions at neutral pH can
potentially present new opportunities for formulating this important
immunoadjuvant. Therefore, it was important to investigate if such
macromolecular interactions take place under physiological conditions. To that
extent, phosphate buffered saline, PBS is an important medium as its relatively
high salt content can have a significant effect on the degree of dissociation and
thereby on the formation of the complex. Fig. 5 shows DLS results for PCPP-PEO
formulations at various molar ratios in PBS. The well-pronounced initial increase
of the hydrodynamic diameter upon addition of PCPP correlates with the results
for the complex formation obtained in phosphate buffer and indicates the apparent
non-covalent ‘grafting’ of PEO chains on PCPP. Some decrease in the molecular
size at higher PEO:PCPP ratios may be associated with moderate compaction of
the assembly due to a larger number of non-covalent cross-links similar to those
described previously for PCPP-protein complexes [7]. The formation of
PCPP-PEO complex under physiological conditions is further supported by a
decline in the Z-potential absolute value indicating the decrease in the surface
concentration of negative charges of PCPP upon complexation.
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3.3. Protein binding capability of PCPP-PEO complexes
The ability of PCPP to form complexes with proteins in aqueous solutions is
one of key features, which is primarily responsible for a peculiar biological
behavior of this macromolecular carrier. Non-covalent interactions with proteins
have been correlated with immunoadjuvant activity, as well as ability to
stabilize proteins in solution and during drying processes [7, 9]. Therefore, it
was important to examine whatever PCPP-PEO complexes are capable of
maintaining this vital function of the polyphosphazene carrier.
Cytochrome C, a protein capable of inducing apoptosis in cancer cells, was used
as a model to investigate binding ability of soluble PCPP-PEO complexes.
Fig. 6 shows the results of protein affinity studies in PBS (pH 7.4). The content
of protein in the complex (loading) was calculated on the basis of unbound
Cytochrome C in the system, which was determined using size exclusion HPLC
with diode array detection. As seen from the Figure, PCPP-PEO complexes
maintain the ability to bind protein and its loading grows with the increase in
Cytochrome C concentration. The results are similar to those for PCPP, which
are also presented in Fig. 6; however, the binding affinity of the complex is
somewhat lower. This can be explained by the fact that some of the potentially
reactive sites on PCPP are already consumed in the formation of PCPP-PEO
complex. The efficiency of protein binding, calculated as a percent of bound
protein in the formulation, also follows PCPP profile, though also at a somewhat
lower level. Overall, although some decrease in the protein binding capacity of
[(Fig._5)TD$FIG]
Fig. 5. Hydrodynamic diameter (1) and zeta potential (2) of PCPP-PEO complexes as a function of
PEO concentration (0.0025% PCPP, PBS, molecular weight of PEO − 100,000 g/mol, pH 7.1).
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PCPP-PEO complexes compared to PCPP was observed, the system is definitely
capable of serving as a protein delivery vehicle.
3.4. PCPP-PEO complexation introduces pH dependent
membrane disruptive activity
One of prerequisites for the development of effective protein drug delivery
vehicles is the ability of macromolecular carrier to facilitate endosomal escape
and deliver payload into the cytosol [23, 24, 25]. This can be achieved through
the pH dependent swelling or aggregation of macromolecule so that the
transition occurs at the pH range corresponding to the pH of early endosomal
environment, usually in the pH range of 5.8–6.6. The feature can be also of
importance for vaccine delivery. Cross-presentation of antigens by dendritic
cells plays central role in the induction of efficient immune responses, especially
CD8+ T-cell responses, which are critical for the immunological control of
tumors and infectious diseases. It has been shown that polymer carriers can
enhance the efficacy of presentation of soluble protein antigen directing it into
the major histocompatibility complex (MHC) class I antigen presentation
pathway [26]. This has been attributed to the ability of polymeric
nanoparticulates or liposomes to increase the amount of antigen that escapes
from endosomes into the cytoplasm [26, 27, 28]. Some polyacids have a
potential to facilitate endosomal escape of proteins through pH sensitive
membrane active behavior, typically through the pH triggered conformational
[(Fig._6)TD$FIG]
Fig. 6. Cytochrome C loading and efficiency of protein binding for PCPP-PEO complexes (1, 2)
and PCPP (3, 4) as a function of protein concentration (0.025% PCPP, 0.01% PEO, molecular
weight of PEO − 100,000 g/mol, PBS, pH 7.4).
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changes and formation of hydrophobic aggregates during the acidification in an
early endosomal environment [17]. However, the membrane disruptive
properties are typically displayed by hydrophobic macromolecules and their
activity does not always correlate with the desirable physiological range.
We investigated the ability of PCPP and its complexes with PEO to disrupt
eukaryotic cell membranes. These studies were conducted using red blood cells
(RBC) as endosomal membrane models [17, 29]. It was found that PCPP does
not possess pH dependent membrane disruptive activity in the pH range 6.3–6.6
and is essentially insoluble at more acidic solutions (Fig. 7A). However,
introduction of polyether and subsequent formation of complexes dramatically
alters this fundamental property of PCPP delivery system. PCPP-PEO
complexes display significant pH dependent membrane destabilizing activity
with a pH threshold dependent on the content of polyether (Fig. 7A). At pH 6.5,
the percent of hemolysis caused by PCPP-PEO complexes correlates well with
the amount of PEO and increases as the concentration of polyether rises
(Fig. 7B). It appears that membrane disruptive activity also follows the pH
triggered growth in the size of aggregates, as detected by DLS (Fig. 7C). It can
be assumed that interpolymer ether − acid bonds in the system result in the
[(Fig._7)TD$FIG]
Fig. 7. Hemolysis of red blood cells by (A) PCPP-PEO complexes as a function of pH at 0.01 (1),
0.02 (2), 0.03 (3) and 0 (4) mg/mL PEO (0.0025% PCPP, PBS); (B) PEO concentration (0.0025%
PCPP, PBS, pH 6.5, molecular weight of PEO − 100,000 g/mol) and (C) hydrodynamic diameter of
complexes as a function of pH at 0.01 (1), 0.02 (2) and 0.03 mg/mL PEO (3). (D) Schematic
presentation of PCPP-PEO complex interaction with cellular membrane.
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establishments of hydrophobic domains and such hydrophobic modification
plays critical role in interactions with cellular membranes (Fig. 7D).
The results demonstrate that preparation of PCPP-PEO complexes introduces pH
dependent membrane disruptive activity into this important immunoadjuvant and
macromolecular delivery system providing new information for further
advancement of mechanistic studies. Moreover, this important biological
property can be easily modulated through variations in the polyether content of
the system suggesting a potential dial-in pH switch approach, which can be
applied more broadly to delivery of macromolecular drugs.
4. Conclusions
The importance of polyphosphazene polyacids, such as PCPP, as clinically
proven potent immunoadjuvants, dictates the need for a better understanding of
their mechanism of action and formulation behavior. One of the important
aspects of this research is the investigation of macromolecular interactions
between polyphosphazenes and formulation excipients. Although, it has been
previously observed that the addition of hydrogen bonding compounds leads to
significant changes in protein stabilizing properties and degradation profiles of
these macromolecules, little was known on the physico-chemical basis of these
phenomena.
The results of present studies provide unambiguous proof of PCPP-PEO
complexation at near physiological conditions. Formation of intermolecular
complexes between polyacids and polyethers, although well studied under acidic
conditions, is highly unusual at neutral pH. Such unique behavior of PCPP can
be probably explained by high ionic density of this macromolecule resulting in
low dissociation constant and, as a consequence, the ability of un-dissociated
acidic groups to form hydrogen bonds in aqueous solutions at neutral pH. Most
importantly, various physical states of the complexes, which span from
nanosized assemblies in solutions to coacervate systems and hydrogel matrices,
provide opportunities for designing new drug delivery systems and biomaterials.
Moreover, it was found that the formation of complexes does not prohibit the
important biologically relevant properties of the carrier, such a protein binding,
which was demonstrated for both soluble and coacervate formulations.
One of the most important findings of the present study is that a simple addition of
polyethers to polyphosphazene carriers can introduce new biological properties in
the system. The pH dependent membrane disruptive activity, which is not
characteristic for PCPP itself, is clearly demonstrated for its interpolymer
complexes. This can be especially important for the design of new intracellular
macromolecular delivery systems, development of new approaches for modulating
biological properties of the existing systems, and provide important insights for
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understanding the relationship between fundamental physico-chemical
characteristics of polyphosphazene immunoadjuvants and their activity in vivo.
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